Department of Laboratory Medicine, Warren Grant Magnuson Clinical Center, Bethesda, MD, USA.
Blood. 2011 Mar 10;117(10):2883-6. doi: 10.1182/blood-2010-07-295501. Epub 2010 Nov 15.
Somatic gain-of-function mutations in members of the RAS subfamily of small guanosine triphosphatases are found in > 30% of all human cancers. We recently described a syndrome of chronic nonmalignant lymphadenopathy, splenomegaly, and autoimmunity associated with a mutation in NRAS affecting hematopoietic cells, and initially we classified the disease as a variant of the autoimmune lymphoproliferative syndrome. Here, we demonstrate that somatic mutations in the related KRAS gene can also be associated with a nonmalignant syndrome of autoimmunity and breakdown of leukocyte homeostasis. The activating KRAS mutation impaired cytokine withdrawal-induced T-cell apoptosis through the suppression of the proapoptotic protein BCL-2 interacting mediator of cell death and facilitated proliferation through p27(kip1) down-regulation. These defects could be corrected in vitro by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1 or phosphatidyl inositol-3 kinase inhibition. We suggest the use of the term RAS-associated autoimmune leukoproliferative disease to differentiate this disorder from autoimmune lymphoproliferative syndrome.
RAS 亚家族小 GTP 酶成员中的体 gain-of-function 突变存在于超过 30%的所有人类癌症中。我们最近描述了一种慢性非恶性淋巴结病、脾肿大和自身免疫的综合征,与影响造血细胞的 NRAS 突变有关,最初我们将该疾病归类为自身免疫性淋巴增生综合征的一种变体。在这里,我们证明相关 KRAS 基因的体细胞突变也可能与非恶性自身免疫和白细胞稳态失调的综合征有关。激活的 KRAS 突变通过抑制促凋亡蛋白 BCL-2 相互作用的细胞死亡介体来抑制细胞因子撤去诱导的 T 细胞凋亡,并通过下调 p27(kip1) 促进增殖。这些缺陷可以通过丝裂原活化蛋白激酶/细胞外信号调节激酶激酶 1 或磷脂酰肌醇-3 激酶抑制在体外得到纠正。我们建议使用术语“RAS 相关自身免疫性白细胞增生性疾病”来区分该疾病与自身免疫性淋巴增生综合征。